Lumexa Imaging (NASDAQ:LMRI) Releases Earnings Results, Beats Expectations By $0.19 EPS

Lumexa Imaging (NASDAQ:LMRI) announced its quarterly earnings data on Tuesday. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.19, FiscalAI reports. The company had revenue of $271.97 million during the quarter.

Here are the key takeaways from Lumexa Imaging’s conference call:

• Q3 systemwide volume grew 4% year over year, with advanced modalities up 8.1% and reaching a record 38.2% of scans. Consolidated revenue was $272 million, while adjusted EBITDA rose 11% sequentially to $62.6 million and margin improved to 23.0%.
• Free cash flow improved to $20.6 million from negative $1.8 million a year earlier, supported by earnings growth, lower interest payments, and more favorable working-capital and JV distribution timing. Management now expects full-year free cash flow conversion of at least 30% of adjusted EBITDA.
• The company narrowed its 2026 adjusted EBITDA guidance to $236 million–$240 million, maintaining the $238 million midpoint, and raised adjusted EPS guidance to $0.86–$0.90, primarily due to a lower assumed tax rate. Revenue guidance was reiterated at $1.045 billion–$1.097 billion.
• Lumexa said the finalized 2027 site-neutral reimbursement rule expands its addressable market from $33 billion to roughly $77 billion, creating a longer-term opportunity to support health systems’ outpatient imaging strategies. It also announced an expanded Advocate Health joint venture that takes the company into Illinois.
• Management’s preliminary assessment is that 2027 Medicare reimbursement will be modestly below its longstanding assumptions—approximately 1% lower—though it expects the overall impact to be limited because Medicare represents about 20% of revenue and most commercial rate negotiations are complete.

Lumexa Imaging Stock Up 13.8%

Shares of NASDAQ:LMRI traded up $1.93 on Wednesday, hitting $15.85. 222,097 shares of the company’s stock were exchanged, compared to its average volume of 676,432. Lumexa Imaging has a 1-year low of $6.45 and a 1-year high of $19.45. The company has a market capitalization of $1.52 billion and a PE ratio of -32.58. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.44 and a current ratio of 1.44. The firm’s 50-day moving average is $11.24 and its 200 day moving average is $11.07.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on LMRI. Weiss Ratings restated a “sell (d)” rating on shares of Lumexa Imaging in a report on Tuesday, September 22nd. Raymond James Financial set a $17.00 price objective on Lumexa Imaging in a research note on Monday, September 28th. KeyCorp started coverage on Lumexa Imaging in a research report on Thursday, September 24th. They set an “overweight” rating and a $18.00 price objective for the company. Barclays boosted their price objective on Lumexa Imaging from $9.00 to $13.00 and gave the stock an “overweight” rating in a research report on Friday, August 28th. Finally, UBS Group restated a “strong-buy” rating on shares of Lumexa Imaging in a research note on Monday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $16.40.

Institutional Investors Weigh In On Lumexa Imaging

Several institutional investors have recently added to or reduced their stakes in LMRI. Jupiter Topco LLC purchased a new stake in shares of Lumexa Imaging during the 2nd quarter worth approximately $24,269,000. Brooklands Fund Management Ltd purchased a new stake in Lumexa Imaging in the third quarter valued at $21,577,000. Janus Henderson Group PLC lifted its position in Lumexa Imaging by 5.4% in the first quarter. Janus Henderson Group PLC now owns 2,100,356 shares of the company’s stock valued at $18,063,000 after acquiring an additional 107,903 shares during the last quarter. BlackRock Inc. acquired a new position in Lumexa Imaging in the second quarter valued at $15,771,000. Finally, Royce & Associates LP boosted its stake in Lumexa Imaging by 25.3% in the third quarter. Royce & Associates LP now owns 988,517 shares of the company’s stock valued at $10,132,000 after acquiring an additional 199,477 shares in the last quarter.

Lumexa Imaging News Summary

These are some of the LMRI news items that stood out recently:

• Positive Sentiment: Several reports described Q3 EPS as beating expectations: one cited $0.26 per share versus a $0.07 consensus, while another reported a 4-cent beat. An earnings article also highlighted interest costs being cut roughly in half, which may have helped earnings. StreetInsider Q3 results Q3 earnings and interest costs
• Neutral Sentiment: LMRI also provided guidance, but the supplied reports do not specify its details, limiting assessment of the outlook. Guidance report
• Negative Sentiment: Results were not uniformly strong: one financial summary lists diluted EPS of $0.07 against a $0.19 estimate, revenue slightly below its $275.3 million estimate, and operating profit down 7.3% year over year. The differing EPS figures across reports make the earnings comparison less clear. Financial summary

About Lumexa Imaging

Lumexa Imaging operates outpatient diagnostic imaging centers that provide radiology services to patients, referring physicians and healthcare providers. Its services include imaging used to help diagnose and monitor a range of medical conditions. The company offers diagnostic procedures such as MRI, CT, PET/CT, mammography, ultrasound and X-ray through its imaging centers and affiliated radiology practices. Lumexa serves communities across the United States, providing an outpatient option for medical imaging outside of a hospital setting.